Breast Cancer Clinical Trials

Showing 2241-2260 of 4,817 trials

HER2 Expression of CTC to Predict Response in HER2-positive Advanced Breast Cancer Patients Treated With ADC

NCT05834686

To evaluate the predictive and prognostic value of HER2 expression of circulating tumor cells in HER2-positive advanced breast cancer patients treated with ADC

Breast Cancer

Beijing 302 Hospital50 participantsStarted Jan 2023

Beijing, Beijing Municipality, China

RECRUITINGPhase 2

Pyrotinib in Women With High-risk in Early Stage Breast Cancer

NCT05834764

ExteNET study explored neratinib prolong anti-HER2 therapy after trastuzumab therapy found that it can improve disease-free survival in patients with lymph nodes positive; In addition, the subgroup of patients with residual tumors after neoadjuvant therapy was found to improve the survival. However, no conclusive conclusions were reached. However, since the study was carried out early so only trastuzumab treatment was used, it is urgent to carry out research that is more in line with current clinical practice and bring more benefits to patients. To explore whether pyrotinib can further reduce the risk of recurrence from previously diagnosed HER2-positive breast cancer after treatment with trastuzumab and pertuzumab or T-DM1.

HER2-positive Breast Cancer

The First Affiliated Hospital with Nanjing Medical University188 participantsStarted Apr 2023

Nanjing, Jiangsu, China

UNKNOWN

HER2 Expression of CTC to Predict Response in HER2-low Advanced Breast Cancer Patients Treated With ADC

NCT05834699

To evaluate the predictive and prognostic value of HER2 expression of circulating tumor cells in HER2-low advanced breast cancer patients treated with ADC

Breast Cancer

Beijing 302 Hospital50 participantsStarted Jan 2023

Beijing, Beijing Municipality, China

HER2 Expression of CTC to Predict Response in HER2-positive Advanced Breast Cancer Patients Treated With ADC

Pyrotinib in Women With High-risk in Early Stage Breast Cancer

HER2 Expression of CTC to Predict Response in HER2-low Advanced Breast Cancer Patients Treated With ADC

Related Searches

Targeted T Cells After Neoadjuvant Chemotherapy in Treating Women With Stage II or III Breast Cancer Undergoing Surgery

Surgery to Remove the Sentinel Lymph Node and Axillary Lymph Nodes After Chemotherapy in Treating Women With Stage II, Stage IIIA, or Stage IIIB Breast Cancer

Second Line ERIbulin Followed by CApecitabine or the Reverse Sequence in HER2-negative Metastatic Breast Cancer Patients

The Impact of Inhalation vs Total Intravenous Anesthesia on the Immune Status and Mortality in Patients Undergoing Breast Cancer Surgery: a Prospective Double-Blind Randomized Clinical Trial.

Red Bull Energy Drink Intake After Autologous Microsurgical Breast Reconstruction

Molecular Imaging of HER2 Expression in HER2-positive Breast Cancer Using 99mTc-ADAPT6 vs 99mTc-DARPinG3

Efficacy of Supplement Adjuvant Capecitabine in HR+/HER2- Breast Cancer Patients With High Risks

ANG1005 in Leptomeningeal Disease From Breast Cancer

Molecular Imaging of HER2 Expression in Breast Cancer Using 99mTc-ZHER2.

99mTc-ADAPT6 SPECT-based Non-invasive Quantification of HER2-expression in Breast Cancer With Metastatic Lymph Nodes

Radiomic Analysis for Predicting Treatment Response and Clinical Outcomes in Malignancies

BREADS: Breast Adjuvant Diet Study

NPWT for Abdominal Incisions in DIEP Reconstructions: A RCT

Neoadjuvant Ontruzant (SB3) in Patients With HER2-positive Early Breast Cancer: An Open-Label (NeoON)

Personalized Estimation of Doses Delivered During Image Guided Radiation Therapy Tests

Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients

Herceptin Followed by Chemotherapy in Treating Women With Metastatic Breast Cancer That Overexpresses HER2